MiDx

MiDx is a company focused on revolutionizing healthcare for individuals with cystic fibrosis through rapid and precise microbial identification. They develop point-of-care lateral flow devices to detect unique biomarkers for bacteria like *Pseudomonas aeruginosa*. This technology allows for the use of various biofluids, including blood, plasma, urine, and saliva, for testing, which is particularly beneficial for patients where traditional sputum cultures are challenging.

The company was founded by Dr. Shaun Robertson and Dr. Simone Lucanto. Their mission is to provide timely and targeted interventions by enabling early and accurate microbial identification, aiming to improve the quality of life for patients. MiDx is currently collaborating with clinical partners to validate its lateral flow device for use in clinical settings, with a future goal of developing it for home use to support community-based care.

Keywords: microbial identification, cystic fibrosis, lateral flow tests, point-of-care diagnostics, Pseudomonas aeruginosa, biomarker detection, non-invasive testing, infectious disease diagnostics, medical devices, clinical validation